Our Science

CD-180

Ground-breaking Platform with Broad Application for Viral and Cancer Applications


The foundation for Abacus’s technology is built on a novel immunotherapeutic platform validated in multiple animal studies. This platform is based upon delivery of antigens (Ags) capable of evoking protective immunity to a receptor expressed just on two major classes of cells that program immune responses. This receptor, CD180 (RP105), normally functions in protective responses to viruses and bacteria. The Abacus platform technology harnesses and directs potent immune responses through CD180. For example, a single injection of a West Nile virus (WNV) Ag targeted to CD180 induces protective immunity in mice to an otherwise lethal WNV infection.1HBV Ags targeted to CD180 induce Ab responses in monkeys that can neutralize the virus and CD4 and CD8 T cells responses as high as those seen in individuals that effectively manage acute HBV infections.

image245

Proof of Concept

Proof of concept for the Abacus Technology – Treatment of Chronic Infectious Diseases such as CHB


There are more than 1.5 million CHB patients in the US and another 300-350 million worldwide living with CHB. Over 25% of CHB patients go on to develop cirrhosis and/or liver cancer. While anti-viral drugs are available to help reduce HBV levels, there is no long-lasting cure for CHB-associated diseases. Targeting HBV Ags into the immune system via CD180 alone or with anti-viral therapy may produce and sustained cure, as seen in individuals acutely infected with HBV who manage the virus through immune control. The market opportunity for CHB patients exceeds $1 billion in the US and $2.5 billion worldwide. Abacus has strong patent protection for the US, EU and Japan markets.


The treatment options for many of these cancer and viral diseases are very limited. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up to infections and cancer. 


This means Abacus is ideally positioned to address a significant market need with active new drug candidates.


image246

Platform Technology

Protective Immunity

Ground-breaking Platform with Broad Application for Viral and Cancer Applications


The foundation for Abacus’s technology is built on a novel immunotherapeutic platform validated in multiple animal studies. This platform is based upon delivery of antigens (Ags) capable of evoking protective immunity to a receptor expressed just on two major classes of cells that program immune responses. This receptor, CD180 (RP105), normally functions in protective responses to viruses and bacteria. The Abacus platform technology harnesses and directs potent immune responses through CD180. For example, a single injection of a West Nile virus (WNV) Ag targeted to CD180 induces protective immunity in mice to an otherwise lethal WNV infection. HBV Ags targeted to CD180 induce Ab responses in monkeys that can neutralize the virus and CD4 and CD8 T cells responses as high as those seen in individuals that effectively manage acute HBV infections.



image247